Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 10/20 | 0.36 |
| ▸ | CNR1 | P21554 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26224372 | 0.86 | TSHR (0.38) | ALDH1A1TSHRMEN1KMT2ACNR2 | |
| SCHEMBL26224382 | 0.85 | CNR2 (0.38) | TSHRCNR2CNR1 | |
| SCHEMBL26224379 | 0.80 | CYP1A2 (0.41) | — | |
| SCHEMBL26224339 | 0.79 | PPARA (0.55) | CNR2CNR1 | |
| SCHEMBL26224335 | 0.77 | LTB4R (0.40) | — | |
| SCHEMBL22525835 | 0.77 | FFAR1 (0.46) | KDM4EALDH1A1L3MBTL1TSHRP4HB | |
| SCHEMBL22527266 | 0.75 | FFAR1 (0.44) | KDM4EALDH1A1L3MBTL1TSHRP4HB | |
| SCHEMBL26224369 | 0.73 | CNR1 (0.40) | CNR2CNR1 | |
| SCHEMBL26224350 | 0.73 | LTB4R (0.41) | CNR2CNR1 | |
| SCHEMBL26203895 | 0.72 | FOS (0.40) | KDM4EALDH1A1L3MBTL1TSHRP4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | KDM4E 414/4885ALDH1A1 2465/4885L3MBTL1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.